Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs

From Decera Clinical Education Oncology Podcast Decera Clinical Education

In this podcast based on a live symposium at the American Society of Clinical Oncology 2024 Annual Meeting, 3 experts discuss the current data and use of SERDs for patients with HR+/HER2- breast cancer.

Community discussion

Join the conversation

Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs

You May Also Like

FluentFiction - Lithuanian

Fluent Fiction - Arabic

FluentFiction - Romanian

Fluent Fiction - Turkish

FluentFiction - Czech

FluentFiction - Bulgarian

Fluent Fiction - Portuguese (Brazil) 🇧🇷

FluentFiction - Slovenian

Fluent Fiction - Hindi

Fluent Fiction - Portuguese (Portugal) 🇵🇹